Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
暂无分享,去创建一个
A. Berrebi | H. Döhner | G. Fingerle-Rowson | M. Hallek | P. Zinzani | S. Stilgenbauer | T. Zenz | D. Winkler | A. Bühler | M. Kneba | P. Staib | B. Cazin | M. Hensel | J. Seymour | M. Trněný | M. Mendila | G. Hess | J. Seymour | S. Böttcher | M. Ritgen | F. caligaris-Cappio | M Hallek | S Böttcher | R. Busch | J. Catalano | F Caligaris-Cappio | K. Fischer | J. Mayer | G Fingerle-Rowson | P Staib | B. Eichhorst | A. Fink | R. Busch | G. Hopfinger | U. V. Grünhagen | M. Bergmann | P. Zinzani | A. Berrebi | U. Jäger | A. Westermann | C. Wendtner | B. Eichhorst | H. Döhner | S. Stilgenbauer | T Zenz | R Busch | M Kneba | K Fischer | AM Fink | J Mayer | M Hensel | G Hopfinger | G Hess | U von Grünhagen | M Bergmann | J Catalano | PL Zinzani | JF Seymour | A Berrebi | U Jäger | B Cazin | M Trneny | A Westermann | CM Wendtner | BF Eichhorst | A Bühler | D Winkler | M Ritgen | M Mendila | H Döhner | S Stilgenbauer | F. Caligaris‐cappio | U. Jäger | G. Hopfinger | Clemens M. Wendtner | Matthias Bergmann | C. Wendtner
[1] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Kimby,et al. Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials , 1999 .
[3] E. Cronkite,et al. Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.
[4] M. Grever,et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. , 1988, Nouvelle revue francaise d'hematologie.
[5] L. Abruzzo,et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy , 2009, Leukemia & lymphoma.
[6] D. Huhn,et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. , 2001, Blood.
[7] M. Grever,et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Lyman,et al. Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[10] W. Knospe,et al. Bi‐weekly chlorambucil treatment of chronic lymphocytic leukemia , 1974 .
[11] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[12] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[13] J. Byrd,et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. , 2005, Blood.
[14] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[15] T. Barbui,et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.
[16] Mark J. Thomas,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.
[17] A. López-Guillermo,et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Everett,et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia , 1992, American journal of hematology.
[19] B. Barlogie,et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. , 1989, Blood.
[20] G. Schwarzer,et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.
[21] E. Montserrat,et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. , 2005, Blood.
[22] G. Brittinger,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.
[23] T Hamblin,et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.
[24] K. Do,et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[26] John C Reed,et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Coiffier,et al. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. , 2009, Blood reviews.
[28] D. Maloney,et al. Rituximab: Mechanism of action and resistance. , 2002, Seminars in oncology.
[29] Steven L. Allen,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[30] V. Diehl,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .
[31] M. James,et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.
[32] H. Kantarjian,et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia , 2009, Cancer.
[33] S. Devesa,et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology , 2007, British journal of haematology.
[34] E. Ezdinli,et al. Chlorambucil vs. combined chlorambucil‐corticosteroid therapy in chronic lymphocytic leukemia , 1973, Cancer.
[35] K. Do,et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. , 2008, Blood.
[36] V. Diehl,et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. , 2002, Blood.
[37] H. Kantarjian,et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] N. Schmitz,et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Hallek,et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.
[40] M. Hallek,et al. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. , 2001, Blood.
[41] D. Weisenburger,et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.